



## Special Article

# Making Health Technology Assessment Information Available for Decision Making: The Development of a Thai Database

Nattiya Kapol PhD\*, Pagamas Maitreemit PhD\*, Rapeepun Chalongsuk MSc (Pharm)\*, Yaowalak Amrumpai PhD\*, Namfon Sribundit MBA\*, Montarat Thavorncharoensap PhD\*\*,\*\*\*, Usa Chaikledkaew MA, PhD \*\*,\*\*\*\*, Yot Teerawattananon MD, PhD\*\*\*

\* Department of Community Pharmacy, Faculty of Pharmacy, Silpakorn University, Nakhon Pathom and Ganesh SAP Research Unit

\*\* Department of Pharmacy, Faculty of Pharmacy, Mahidol University, Bangkok

\*\*\* Health Intervention and Technology Assessment Program (HITAP), Ministry of Public Health, Nonthaburi

In Thailand, there is an attempt to develop the Thai HTA database in order to improve the accessibility and usefulness of HTA information. At present, the database is available online at [www.db.hitap.net](http://www.db.hitap.net). The database includes 1) economic evaluation studies i.e. cost-minimization analysis, cost-effectiveness analysis, cost-benefit analysis, and cost-utility analysis, 2) outcome assessment studies i.e. randomized controlled trials, and 3) quantitative measured quality of life studies. All HTA studies related to the Thai context, and published in either Thai or English from 1990 onward, are eligible for inclusion in the database. In addition, there is a quality evaluation for each economic evaluation study which will help readers, who have limited knowledge about the method, to understand and make appropriate use of the information in their own settings. This may also raise awareness among researchers, who will conduct economic evaluation studies in the future, to adhere to the standard methodological guidelines because the quality evaluation was developed based on the national guidelines published in this supplement journal.

**Keywords:** Health technology assessment, Database, Economic evaluation

**J Med Assoc Thai 2008; 91 (Suppl 2): S8-10**

**Full text. e-Journal:** <http://www.medassothai.org/journal>

Health technologies, including pharmaceuticals, medical devices, procedures, and health prevention and promotion, at both individual and community levels are an important part of health care systems, and form a significant proportion of health expenditure worldwide. Health technology assessment (HTA) is, therefore, considered as an important tool for assisting decision makers in appraising whether a particular health technology is effective, appropriate and efficient<sup>(1)</sup>.

*Correspondence to:* Teerawattananon Y, Health Intervention and Technology Assessment Program (HITAP), 6<sup>th</sup> Floor 6<sup>th</sup> Building, Department of Health, Ministry of Public Health, Tiwanon Rd., Nonthaburi 11000, Thailand. Phone: 0-2590-4549, Fax: 0-2590-4369, E-mail: [yot@ihpp.thaigov.net](mailto:yot@ihpp.thaigov.net)

There are two distinct operational cultures within a health care system that could limit the use of HTA information in decision making. On one hand, decision-makers, including policy-makers at national and hospital levels, are often working in a very tight timeframe. They rarely wait for evidence before making their decisions. On the other hand, academics seeking a research result prefer to work within longer timeframes. They like to ensure that they conduct a perfect study. HTA will have a limited impact on policy if it is not available at the right time for making decisions. For example, by the time HTA data are available or published, it is often too late to include the information in the coverage decision because the new technology has already become established. This is also an



important barrier to subsequent changes based on HTA data, because once a technology or intervention has become standard practice, restricting its use becomes much more difficult.

Two ways to improve the availability of information for decision-making are suggested here. First, it is recommended that HTA should be planned and used in a systematic manner rather than on an *ad hoc* basis. It is possible for HTA studies to be conducted and used routinely as a source of information, for example, for the pharmaceuticals listed on the Pharmaceutical Benefit Schedule in Australia<sup>(2)</sup>, or they can be used with a clear and planned timeline for evaluations as is the practice by NICE in England and Wales<sup>(3)</sup>. Second, if HTA information is to be introduced for decision-making at every level, having access to reliable HTA data for competing health technology is very important. The latter recommendation is also in line with the development of HTA databases in many settings<sup>(4)</sup>.

During the past decades, although there has been an increasing number of HTA studies related to the Thai setting<sup>(5)</sup>, a limitation of the Thai HTA database limits the accessibility of the information and, subsequently, the use of HTA in decision-making. As a result, searching for HTA information becomes a time-consuming procedure. Many HTA studies have been published in grey literature such as theses, dissertations, conference proceedings and research reports and that makes it more difficult for the reviewers. In Thailand, there is an attempt to develop the Thai HTA database in order to improve the accessibility and usefulness of HTA information. This is a collaborative project between the Ganesh SAP Research Unit, the Silpakorn University and the Health Intervention Technology Assessment Program (HITAP) with support from the Health Systems Research Institute, the Thai Health Promotion Foundation, and the Bureau of Policy and Strategy, Ministry of Public Health.

At present, the database is available online at [www.db.hitap.net](http://www.db.hitap.net). The database includes 1) economic evaluation studies *i.e.* cost-minimization analysis, cost-effectiveness analysis, cost-benefit analysis, and cost-utility analysis, 2) outcome assessment studies *i.e.* randomized controlled trials, and 3) quantitative measured quality of life studies. All HTA studies

related to the Thai context, and published in either Thai or English from 1990 onward, are eligible for inclusion in the database. The database will be updated regularly. In addition, one of the most important initiatives of the database is that there is a quality evaluation for each economic evaluation study which will help readers, who have limited knowledge about the method, to understand and make appropriate use of the information in their own settings. This may also raise awareness among researchers, who will conduct economic evaluation studies in the future, to adhere to the standard methodological guidelines because the quality evaluation was developed based on the national guidelines published in this supplement journal.

Lastly, given a better HTA infrastructure *i.e.* the methodological guidelines and the HTA database, we hope that proper policy and strategies can be developed to improve the allocation and use of health technology instead of the imprecise, inconsistent and unaccountable practices of prioritization which still exist in the Thai health care system today.

## References

1. Goodman CS. Introduction to health care technology assessment. Bethesda, MD: U.S. National Library of Medicine; 2004.
2. Wonder MJ, Neville AM, Parsons R. Are Australians able to access new medicines on the pharmaceutical benefits scheme in a more or less timely manner? An analysis of pharmaceutical benefits advisory committee recommendations, 1999-2003. *Value Health* 2006; 9: 205-12.
3. Towse A, Pritchard C. National Institute for Clinical Excellence (NICE): Is economic appraisal working? *Pharmacoeconomics* 2002; 20(Suppl 3): 95-105.
4. Nixon J, Ulmann P, Glanville J, Boulenger S, Drummond M, de Pouvourville G. The European Network of Health Economic Evaluation Databases (EURO NHEED) Project. *Eur J Health Econ* 2004; 5: 183-7.
5. Teerawattananon Y, Russell S, Mugford M. A systematic review of economic evaluation literature in Thailand: are the data good enough to be used by policy-makers? *Pharmacoeconomics* 2007; 25: 467-79.



---

## การส่งเสริมให้มีข้อมูลการประเมินเทคโนโลยีด้านสุขภาพสำหรับผู้กำหนดนโยบาย: การพัฒนาฐานข้อมูลสำหรับประเทศไทย

ณัฏฐ์ภิญญา คำผล, ผกามาศ ไมตรีมิตร, ระพีพรรณ ฉลองสุข, เยาวลักษณ์ อ้ำรำไพ, น้ำฝน ศรีบันทิต,  
มนตรีต้ม ถาวรเจริญทรัพย์, อุษา ฉายเกล็ดแก้ว, ยศ ตีระวัฒนาวนนท์

เพื่อเพิ่มการเข้าถึงและใช้ประโยชน์จากการวิจัยที่เกี่ยวกับการประเมินเทคโนโลยีด้านสุขภาพ คณะกรรมการพนักงานวิจัยฯ ได้พัฒนาฐานข้อมูลสำหรับประเทศไทย ซึ่งปัจจุบันสามารถสืบค้นได้จาก [www.db.hitap.net](http://www.db.hitap.net) โดยฐานข้อมูลดังกล่าว ประกอบด้วย 1) งานวิจัยด้านการประเมินความคุ้มค่าทางการแพทย์ ทุกวิธีการวิเคราะห์ ได้แก่ ต้นทุนต่ำสุด ต้นทุนประสิทธิผล ต้นทุนผลได้ และต้นทุนของรถประจำปี 2) งานวิจัยด้านการประเมินผลลัพธ์ เช่น การทดลองแบบสุ่ม ที่มีเกลลั่มเปรียบเทียบ 3) งานวิจัยด้านการวัดคุณภาพชีวิต ทั้งนี้ฐานข้อมูลดังกล่าว รวบรวมงานวิจัยการประเมินเทคโนโลยีด้านสุขภาพ ในบริบทของประเทศไทย ที่ตีพิมพ์ทั้งภาษาไทยและภาษาอังกฤษ ตั้งแต่ปี พ.ศ. 2533 เป็นต้นมา นอกจากนี้ยังมีการประเมินคุณภาพงานวิจัย ซึ่งช่วยให้ผู้อ่านที่มีความรู้จำกัด เกี่ยวกับระเบียบวิธีวิจัย สามารถเข้าใจ และนำข้อมูลจากการวิจัยไปประยุกต์ใช้อย่างเหมาะสมต่อไป และอาจกระตุ้นให้นักวิจัยที่จะทำงานวิจัยด้านการประเมินความคุ้มค่าทางการแพทย์ยึดถือเป็นมาตรฐาน ตามคำแนะนำในคู่มือการประเมินเทคโนโลยีด้านสุขภาพ สำหรับประเทศไทย